ArticleHepatic oncology2020
HCC occurrence after DAA treatments: molecular tools to assess the post-treatment risk and surveillance.
Devis Pascut et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
8 papers cite it
this papercites it